<DOC>
	<DOCNO>NCT00811928</DOCNO>
	<brief_summary>A randomized , open label parallel control , multicenter study evaluate safety efficacy Posaconazole oral suspension v Fluconazole ( capsule ) high-risk leukopenic patient prevention invasive fungal infection</brief_summary>
	<brief_title>Safety Efficacy Study Posaconazole vs. Fluconazole Prevention Invasive Fungal Infection ( P05387 AM1 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Leukopenia</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Participants must 1870 year age either sex Persistent neutropenia ( Absolute Neutrophil Count [ ANC ] &lt; 500/mm^3 [ 0.5x10^9/L ] ）or probable neutropenia 35 day anticipate . Neutropenia &gt; = 7 day cause follow reason Standard doseintense chemotherapy , anthracyclines acceptable chemotherapy ( investigational drug permit ) Acute Myelogenous Leukemia ( AML ) treatment Retreatment chemotherapy case AML recurrence Myelodysplastic syndrome ( MDS ) shift AML bone marrow arrest induction chemotherapy require ( include acute phase chronic myelogenous leukemia [ CML ] ) Informed consent obtain participant legal guardian Participants previously treat amphotericin B ( AMB ) , fluconazole ( FLZ ) , itraconazole ( ITZ ) within 30 day enrollment . Participants take follow drug : terfenadine , cisapride , ebastine within 24 hour entry astemizole entry within 10 day entry cimetidine , rifampin , carbamazepine , phenytoin , rifabutin , barbiturate , isoniazid atharanthine anthracyclines within 24 hour entry The drug refrain investigation Serious organ diseases except hematological disorder cardiac neurologic disorder impairment expect unstable progressive course study ( eg , seizures demyelinate syndrome , acute myocardial infarction within 3 month study entry , myocardial ischemia , congestive heart failure , atrial fibrillation ventricular rate &lt; 60/min , history torsades de pointes , symptomatic ventricular sustain arrhythmia ) , unstable electrolyte abnormality . Participants use investigational drug biologic agent chemotherapy regimen within 30 day study entry . Prior enrollment study . Participants know suspected hypersensitivity idiosyncratic reaction azole agent amphotericin B . Participants know suspected invasive fungal infection ( IFI ) screen Participants severe renal insufficiency ( estimate creatinine clearance le 50 mL/minute likely require dialysis study ) , Alanine transaminase ( ALT ) , Aspartate transaminase ( AST ) , alkaline phosphatase total bilirubin &gt; 2× ( Upper Limit Normal ) ULN . Participants electrocardiogram ( ECG ) prolong QTc interval : QTc great 450 msec men great 470 msec woman . Participants AML CML history . Participants history allogeneic hematopoietic stem cell , bone marrow transplantation , autologous stem cell transplantation history . Female participant pregnant nursing . Alcohol and/or drug abuse . Participants compliant opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>high-risk leukopenic patient</keyword>
</DOC>